search
Back to results

Oxygen Control and Weaning by O2matic to Patients Admitted With an Exacerbation of COPD (O2MATIC-WEAN)

Primary Purpose

COPD Exacerbation, Hypoxia, Hypoxemia

Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
O2matic
Sponsored by
Hvidovre University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for COPD Exacerbation focused on measuring closed-loop, oxygen treatment

Eligibility Criteria

35 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • COPD verified by Forced Expiratory Volume in 1. second (FEV1) divided by Forced Vital Capacity (FVC) < 0,70
  • Admission due to exacerbation in COPD
  • COPD exacerbation and pneumonia can be included
  • Expected duration of admission > 48 hours
  • Need for oxygen supplementation (SpO2 <= 88 % on room air)
  • Cognitively able to participate in the study
  • Willing to participate and give informed consent

Exclusion Criteria:

  • Need or anticipated need for mechanical ventilation (intermittent Continuous Positive Airway Pressure (CPAP) is allowed)
  • Major comorbidities causing hypoxemia (Cancer, heart disease, pulmonary emboli)
  • Asthma or other respiratory condition requiring higher SpO2 than normal for COPD
  • Pregnancy
  • Cognitive barriers for participation

Sites / Locations

  • Bispebjerg University Hospital
  • Nordsjællands Hospital
  • Gentofte University Hospital
  • Herlev University Hospital
  • Hvidovre University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

O2matic

Manual

Arm Description

Usual care plus O2matic controlled oxygen therapy for a maximum of 3 days or until weaning from oxygen supplementation

Usual care plus manual controlled oxygen therapy by nursing staff. O2matic used in monitoring mode to measure SpO2 continuously.

Outcomes

Primary Outcome Measures

Time to weaning from oxygen supplementation
Time to weaning from oxygen supplementation in O2matic and manual arm (Patients will be followed for this outcome during the admission, up to 30 days)

Secondary Outcome Measures

Number of patients weaned from oxygen supplementation after day 1
Fraction of patients weaned from oxygen supplementation after 1 day in O2matic and manual arm
Number of patients weaned from oxygen supplementation after day 3
Fraction of patients weaned from oxygen supplementation after 3 days in O2matic and manual arm
Time within SpO2 interval
Fraction of time within prescribed SpO2 interval in O2matic and manual arm
Time with severe hypoxemia
Fraction of time with SpO2 < 85 % in O2matic and manual arm
Time with minor hypoxemia
Fraction of time with SpO2 below target but not below 85 % in O2matic and manual arm
Time with hyperoxia
Fraction of time with SpO2 above target in O2matic and manual arm
Sensation of safety
Patients sensation of safety measured by Visual Analog Scale (VAS) score in O2matic and manual arm
Sensation of anxiety
Patients sensation of anxiety measured by Hospital Anxiety and Depression (HADS-A ) subscale in O2matic and manual arm
Sensation of dyspnea
Patients sensation of dyspnea measured by Multidimensional Dyspnea Profile (MDP) in O2matic and manual arm
Time to discharge
Time from admission to discharge from hospital

Full Information

First Posted
September 1, 2018
Last Updated
September 19, 2022
Sponsor
Hvidovre University Hospital
Collaborators
Innovation Fund Denmark
search

1. Study Identification

Unique Protocol Identification Number
NCT03661086
Brief Title
Oxygen Control and Weaning by O2matic to Patients Admitted With an Exacerbation of COPD
Acronym
O2MATIC-WEAN
Official Title
Oxygen Control and Weaning by O2matic to Patients Admitted With an Exacerbation of COPD
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Completed
Study Start Date
December 1, 2018 (Actual)
Primary Completion Date
June 30, 2022 (Actual)
Study Completion Date
June 30, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hvidovre University Hospital
Collaborators
Innovation Fund Denmark

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of the study is to examine if automated oxygen delivery with O2matic allows for faster weaning from oxygen and better oxygen control than manually controlled oxygen therapy for patients admitted with an exacerbation of chronic obstructive pulmonary disease (COPD). Furthermore it will be tested if O2matic compared to manual control allows for faster discharge from hospital. Patients sense of security, anxiety and dyspnea will be evaluated by questionnaires.
Detailed Description
Closed-loop control of oxygen therapy is described in the literature used for preterm infants, trauma patients, medical emergency use and patients with COPD. For the latter, closed-loop therapy has been used for patients admitted to hospital with an exacerbation, for domiciliary oxygen use and during exercise. O2matic is a closed-loop system that is based on continuous and non-invasive measurement of pulse and oxygen-saturation (SpO2). The algorithm in O2matic controls oxygen delivery with the aim of keeping the SpO2 within the desired interval, which could be 88-92 % for COPD-patients in accordance with international guidelines on this topic. SpO2-interval can be set for the individual patients, as can the range of acceptable oxygen-flow. If SpO2 or oxygen-flow cannot be maintained within the desired intervals an alarm will sound. All studies on closed-loop systems have shown that this method is better than manually control by nurse to maintain saturation within the desired interval. Furthermore, some studies have indicated that closed-loop has the possibility to reduce admission time and to reduce time spent with oxygen therapy, due to more efficient and fast withdrawal from oxygen supplementation. In the present study O2matic will be tested versus manual control, for patients admitted with an exacerbation in COPD, and in need of supplemental oxygen. During the study the patients will either have oxygen controlled with O2matic or manually by nursing staff for 3 consecutive days. All patients will have continuous logging of pulse, oxygen-saturation and oxygen-flow with O2matic, but only in the O2matic active group, the algorithm will control oxygen-delivery. The primary hypothesis is that O2matic compared to manual control allows for faster weaning from oxygen supplementation, and that more patients will be weaned from oxygen supplementation within a time frame of 3 days. Furthermore it will be tested if O2matic compared to manual control leads to faster achieved respiratory stability, allowing for hospital discharge. It will be tested if O2matic is better than manual control in maintaining oxygen-saturation within the desired interval and reducing time with unintended hypoxia and hyperoxia. Patients sense of security and feeling of anxiety and dyspnea will be evaluated by questionnaires. No safety issues has been reported in the literature. O2matic is approved for clinical testing by The Danish Medicines Agency, The Ethics Committee in the Capital Region of Denmark and by the regional Data Protection Board. The study will be conducted according to Good Clinical Practice (GCP) standards with independent monitoring. All adverse events and serious adverse events will be monitored and serious adverse events will be reported to Danish Medicines Agency.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COPD Exacerbation, Hypoxia, Hypoxemia, Hyperoxia, Respiratory Failure, Respiratory Insufficiency, Copd Exacerbation Acute
Keywords
closed-loop, oxygen treatment

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Open label randomized controlled parallel study
Masking
None (Open Label)
Allocation
Randomized
Enrollment
157 (Actual)

8. Arms, Groups, and Interventions

Arm Title
O2matic
Arm Type
Active Comparator
Arm Description
Usual care plus O2matic controlled oxygen therapy for a maximum of 3 days or until weaning from oxygen supplementation
Arm Title
Manual
Arm Type
No Intervention
Arm Description
Usual care plus manual controlled oxygen therapy by nursing staff. O2matic used in monitoring mode to measure SpO2 continuously.
Intervention Type
Device
Intervention Name(s)
O2matic
Intervention Description
O2matic controls oxygen with the aim of maintaining SpO2 within a predefined target interval, e.g. 88-92 % with the lowest possible supplementation of oxygen by nasal cannula
Primary Outcome Measure Information:
Title
Time to weaning from oxygen supplementation
Description
Time to weaning from oxygen supplementation in O2matic and manual arm (Patients will be followed for this outcome during the admission, up to 30 days)
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Number of patients weaned from oxygen supplementation after day 1
Description
Fraction of patients weaned from oxygen supplementation after 1 day in O2matic and manual arm
Time Frame
1 day
Title
Number of patients weaned from oxygen supplementation after day 3
Description
Fraction of patients weaned from oxygen supplementation after 3 days in O2matic and manual arm
Time Frame
3 days
Title
Time within SpO2 interval
Description
Fraction of time within prescribed SpO2 interval in O2matic and manual arm
Time Frame
3 days
Title
Time with severe hypoxemia
Description
Fraction of time with SpO2 < 85 % in O2matic and manual arm
Time Frame
3 days
Title
Time with minor hypoxemia
Description
Fraction of time with SpO2 below target but not below 85 % in O2matic and manual arm
Time Frame
3 days
Title
Time with hyperoxia
Description
Fraction of time with SpO2 above target in O2matic and manual arm
Time Frame
3 days
Title
Sensation of safety
Description
Patients sensation of safety measured by Visual Analog Scale (VAS) score in O2matic and manual arm
Time Frame
3 days
Title
Sensation of anxiety
Description
Patients sensation of anxiety measured by Hospital Anxiety and Depression (HADS-A ) subscale in O2matic and manual arm
Time Frame
3 days
Title
Sensation of dyspnea
Description
Patients sensation of dyspnea measured by Multidimensional Dyspnea Profile (MDP) in O2matic and manual arm
Time Frame
3 days
Title
Time to discharge
Description
Time from admission to discharge from hospital
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: COPD verified by Forced Expiratory Volume in 1. second (FEV1) divided by Forced Vital Capacity (FVC) < 0,70 Admission due to exacerbation in COPD COPD exacerbation and pneumonia can be included Expected duration of admission > 48 hours Need for oxygen supplementation (SpO2 <= 88 % on room air) Cognitively able to participate in the study Willing to participate and give informed consent Exclusion Criteria: Need or anticipated need for mechanical ventilation (intermittent Continuous Positive Airway Pressure (CPAP) is allowed) Major comorbidities causing hypoxemia (Cancer, heart disease, pulmonary emboli) Asthma or other respiratory condition requiring higher SpO2 than normal for COPD Pregnancy Cognitive barriers for participation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jørgen Vestbo, DMSc
Organizational Affiliation
Manchester University Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Bispebjerg University Hospital
City
Copenhagen
ZIP/Postal Code
2400
Country
Denmark
Facility Name
Nordsjællands Hospital
City
Frederikssund
ZIP/Postal Code
3600
Country
Denmark
Facility Name
Gentofte University Hospital
City
Hellerup
ZIP/Postal Code
2900
Country
Denmark
Facility Name
Herlev University Hospital
City
Herlev
ZIP/Postal Code
2730
Country
Denmark
Facility Name
Hvidovre University Hospital
City
Hvidovre
ZIP/Postal Code
2650
Country
Denmark

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
22288082
Citation
Rice KL, Schmidt MF, Buan JS, Lebahn F, Schwarzock TK. AccuO2 oximetry-driven oxygen-conserving device versus fixed-dose oxygen devices in stable COPD patients. Respir Care. 2011 Dec;56(12):1901-5.
Results Reference
background
PubMed Identifier
21255511
Citation
Cirio S, Nava S. Pilot study of a new device to titrate oxygen flow in hypoxic patients on long-term oxygen therapy. Respir Care. 2011 Apr;56(4):429-34. doi: 10.4187/respcare.00983. Epub 2011 Jan 21.
Results Reference
background
PubMed Identifier
22348812
Citation
Lellouche F, L'her E. Automated oxygen flow titration to maintain constant oxygenation. Respir Care. 2012 Aug;57(8):1254-62. doi: 10.4187/respcare.01343. Epub 2012 Feb 17.
Results Reference
background
PubMed Identifier
27601891
Citation
Lellouche F, Bouchard PA, Roberge M, Simard S, L'Her E, Maltais F, Lacasse Y. Automated oxygen titration and weaning with FreeO2 in patients with acute exacerbation of COPD: a pilot randomized trial. Int J Chron Obstruct Pulmon Dis. 2016 Aug 24;11:1983-90. doi: 10.2147/COPD.S112820. eCollection 2016.
Results Reference
background
PubMed Identifier
27794080
Citation
Lellouche F, L'Her E, Bouchard PA, Brouillard C, Maltais F. Automatic Oxygen Titration During Walking in Subjects With COPD: A Randomized Crossover Controlled Study. Respir Care. 2016 Nov;61(11):1456-1464. doi: 10.4187/respcare.04406. Epub 2016 Oct 18.
Results Reference
background
PubMed Identifier
28729473
Citation
L'Her E, Dias P, Gouillou M, Riou A, Souquiere L, Paleiron N, Archambault P, Bouchard PA, Lellouche F. Automatic versus manual oxygen administration in the emergency department. Eur Respir J. 2017 Jul 20;50(1):1602552. doi: 10.1183/13993003.02552-2016. Print 2017 Jul.
Results Reference
background
PubMed Identifier
30587955
Citation
Hansen EF, Hove JD, Bech CS, Jensen JS, Kallemose T, Vestbo J. Automated oxygen control with O2matic(R) during admission with exacerbation of COPD. Int J Chron Obstruct Pulmon Dis. 2018 Dec 14;13:3997-4003. doi: 10.2147/COPD.S183762. eCollection 2018.
Results Reference
background
Links:
URL
http://O2matic.com
Description
Background and description of the O2matic device

Learn more about this trial

Oxygen Control and Weaning by O2matic to Patients Admitted With an Exacerbation of COPD

We'll reach out to this number within 24 hrs